Sellas Life Sciences is trading 4.37% up now at $12.05, rebounding after its 14.42% decline on September 11, 2026; no verified company-specific catalyst explains the September 14, 2026 intraday gain.
- Recent reports discuss a securities-law investigation tied to delayed disclosure of the Phase 3 GPS trial’s 80th-patient-death milestone.
- That issue appears related to the prior selloff rather than today’s rebound; broader markets are lower, so market direction does not clearly explain the move.